Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments.

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

Prostate cancer ranks among the most common health challenges men face worldwide. While medical advances continue to improve treatment outcomes, the e ...

Metastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have slower-growing cancer and a better prognosis. Researchers are developing ...

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

According to GlobalData, Phase II drugs for Hormone-Sensitive Prostate Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into ... is for the treatment of ...

Postmenopausal Hormone Replacement Therapy and Breast Cancer ... Log-log plot of age specific incidence rates for breast cancer (per 100,000) in US white women, 1969-1971. From Cutler SY, Young ...

A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat ...